Patent · US Active

Predictive biomarker for cancer therapy

US10006032B2 · kind B2 · utility

4Cited by

0References

6Claims

0Family size

Assignee

Mologen AG · DE

Inventors

Matthias Schroff · Berlin, DE
Manuel Schmidt · Berlin, DE
Kerstin Kapp · Berlin, DE
Burghardt Wittig · Berlin, DE

Key dates

Filing date	May 15, 2014
Grant date	Jun 26, 2018
Priority date	—
Expiry date	May 15, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.